ENERGENESIS (6657) reported revenue of NT$386,000 for Oct 2026, -66.1% year on year and -11.1% from the previous month. Revenue for Jan–Oct 2026 was NT$5.5 million (-8.6% year on year).
In Oct 2026, it ranked No. 150 by revenue among 160 Biotech & Medical companies.
Monthly revenue chart
Hover over (or tap) a bar to see that month’s revenue.
Monthly revenue history
| Month | Revenue | YoY | MoM |
|---|---|---|---|
| Oct 2026 | NT$386,000 | -66.1% | -11.1% |
| Sep 2026 | NT$434,000 | -43.8% | -46.0% |
| Aug 2026 | NT$803,000 | +153.3% | +30.8% |
| Jul 2026 | NT$614,000 | +24.5% | +22.3% |
| Jun 2026 | NT$502,000 | -45.7% | -7.2% |
| May 2026 | NT$541,000 | -24.1% | -33.1% |
| Apr 2026 | NT$809,000 | +89.9% | +10.8% |
| Mar 2026 | NT$730,000 | +50.2% | +170.4% |
| Feb 2026 | NT$270,000 | -8.5% | -30.9% |
| Jan 2026 | NT$391,000 | -9.5% | -65.1% |
| Dec 2025 | NT$1.1 million | +86.8% | +102.0% |
| Nov 2025 | NT$555,000 | -50.2% | -51.3% |
| Oct 2025 | NT$1.1 million | +29.1% | +47.5% |
| Sep 2025 | NT$772,000 | +69.7% | +143.5% |
| Aug 2025 | NT$317,000 | -69.8% | -35.7% |
| Jul 2025 | NT$493,000 | -19.2% | -46.7% |
| Jun 2025 | NT$925,000 | +174.5% | +29.7% |
| May 2025 | NT$713,000 | -8.2% | +67.4% |
| Apr 2025 | NT$426,000 | -17.4% | -12.3% |
| Mar 2025 | NT$486,000 | -35.3% | +64.7% |
| Feb 2025 | NT$295,000 | +22.4% | -31.7% |
| Jan 2025 | NT$432,000 | +3.8% | -28.0% |
| Dec 2024 | NT$600,000 | -2.4% | -46.1% |
| Nov 2024 | NT$1.1 million | +10.8% | +26.3% |
| Oct 2024 | NT$882,000 | +43.4% | +93.8% |
Jan–Oct 2026 cumulative: NT$5.5 million (-8.6% YoY)
Other Biotech & Medical companies
Compare with peers: ENERGENESIS vs PEC / ENERGENESIS vs Lotus Pharm / ENERGENESIS vs Bora
| Company | Revenue | YoY |
|---|---|---|
| PEC | NT$2.84 billion | +102.0% |
| Lotus Pharm | NT$2.13 billion | -22.5% |
| Bora | NT$1.99 billion | +15.9% |
| Great Tree Pharmacy | NT$1.67 billion | +1.5% |
| EXCELSIOR | NT$1.02 billion | +38.6% |
| PEGAVISION | NT$793 million | +13.0% |
| Synmosa Biopharma | NT$766.6 million | +41.2% |
| Y.S.H. | NT$749.4 million | +4.4% |
Company remark (original Chinese)
主要係試劑銷售及勞務收入皆減少
See also
← All Taiwan listed & OTC companies
Sources: Taiwan Stock Exchange, monthly revenue of listed companies (Government Open Data Platform); Taipei Exchange, monthly revenue of OTC companies (TPEx OpenAPI); historical months from MOPS. Amounts in New Taiwan dollars. Changes calculated by this site from the source figures. Not investment advice. Updated: 2026-11-16